This article was originally published in The Gray Sheet
Inks agreement to sell $15 mil. in convertible zero coupon debentures to investment funds managed by Brown Simpson Asset Management, LLC and Rose Glen Capital Management, L.P., bringing total cash available to $56 mil. The securities are convertible at $10 per share at the company's option "when the common stock has traded at a certain premium to the fixed conversion price for five (5) consecutive trading days." The Menlo Park, California-based developer of therapeutic drugs and diagnostic products plans to use the proceeds to accelerate programs related to "recent discoveries in embryonic stem cell technology as well as our telomerase programs"
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.